Expertise in
3
conditions

Dr. Craig Erker

Hematology | Oncology
Childrens Hospital Of Wisconsin
9000 W Wisconsin Ave, 
Milwaukee, WI 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
3
conditions
Childrens Hospital Of Wisconsin
9000 W Wisconsin Ave, 
Milwaukee, WI 

Overview

Craig Erker is a Hematologist and an Oncologist practicing medicine in Milwaukee, Wisconsin.

Dr. Erker is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Glioma, Embryonal Tumor with Multilayered Rosettes, Medulloblastoma, Bone Marrow Aspiration, and Embolectomy.

He is actively involved in clinical research, co-authoring 43 peer reviewed articles and participating in 23 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatrics in WI

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Childrens Hospital of Wisconsin
9000 W Wisconsin Ave, Milwaukee, WI 53226

Additional Areas of Focus

Dr. Erker has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

23 Clinical Trials

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: March 31, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 3
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Enrollment Status: Recruiting
Publish Date: February 27, 2026
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Busulfan, Carboplatin, Cisplatin, Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Etoposide Phosphate, Isotretinoin, Melphalan Hydrochloride, Sargramostim, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
Study Phase: Phase 3
Health Related Quality of Life (HRQL) and Symptom Assessment in Patients Diagnosed With Diffuse Intrinsic Pontine Glioma (DIPG) or Recurrent and Re-irradiated Brain Tumours and Their Caregivers: A Non-Therapeutic Study
Health Related Quality of Life (HRQL) and Symptom Assessment in Patients Diagnosed With Diffuse Intrinsic Pontine Glioma (DIPG) or Recurrent and Re-irradiated Brain Tumours and Their Caregivers: A Non-Therapeutic Study
Enrollment Status: Completed
Publish Date: April 15, 2026
Intervention Type: Other
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, Filgrastim, Nivolumab, Pegfilgrastim, Prednisolone, Prednisone, Rituximab, Rituximab+Hyaluronidase Human, Vincristine Sulfate
Study Phase: Phase 3
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological, Radiation
Study Drugs: Erwinia Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug
Study Drug: Tyrosine Kinase Inhibitor
Study Phase: Phase 2
StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors
StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors
Enrollment Status: Active_not_recruiting
Publish Date: February 27, 2026
Intervention Type: Other, Behavioral, Device
Study Phase: Phase 3
View 8 Less Clinical Trials

43 Total Publications

Correction: National multicentered retrospective review of salvage therapy for pediatric medulloblastoma: a Canadian experience.
Correction: National multicentered retrospective review of salvage therapy for pediatric medulloblastoma: a Canadian experience.
Journal: Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
Published: January 14, 2026
Similar Doctors
Expertise in
3
conditions
Dr. Robert Montgomery
Hematology | Oncology
Expertise in
3
conditions
Dr. Robert Montgomery
Hematology | Oncology

Childrens Hospital Of Wisconsin Inc

8915 W Connell Ave, 
Milwaukee, WI 
 (325.9 miles away)
414-257-2424
Languages Spoken:
English
See accepted insurances

Robert Montgomery is a Hematologist and an Oncologist practicing medicine in Milwaukee, Wisconsin. Dr. Montgomery is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Von Willebrand Disease (VWD), Blood Clots, Hemophilia A, Hemophilia B, and Bone Marrow Transplant.

Expertise in
5
conditions
Dr. Amanda Brandow
Hematology | Oncology
Expertise in
5
conditions
Dr. Amanda Brandow
Hematology | Oncology

Milwaukee Campus-Children's Wisconsin

8915 W Connell Ave, 
Milwaukee, WI 
 (325.9 miles away)
414-266-2000
Languages Spoken:
English
See accepted insurances

Amanda Brandow is a Hematologist and an Oncologist practicing medicine in Milwaukee, Wisconsin. Dr. Brandow is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia.

Expertise in
12
conditions
Dr. Mary Eapen
Hematology | Oncology
Expertise in
12
conditions
Dr. Mary Eapen
Hematology | Oncology

Clinical Cancer Center-Froedtert Hospital

8800 W Doyne Ave, 
Milwaukee, WI 
 (325.8 miles away)
414-805-0505
Languages Spoken:
English
See accepted insurances

Mary Eapen is a Hematologist and an Oncologist practicing medicine in Milwaukee, Wisconsin. Dr. Eapen is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Graft Versus Host Disease (GvHD), Anemia, Aplastic Anemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Craig Erker

How do I make an appointment with Dr. Craig Erker?

You can book an appointment with Dr. Craig Erker by calling their office at 414-805-3666. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Craig Erker a top-rated expert for Glioma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Craig Erker is classified as an Advanced expert for Glioma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Craig Erker specialize in?

While Dr. Craig Erker is a Hematology, they have specific expertise in Glioma, Embryonal Tumor with Multilayered Rosettes, and Medulloblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Craig Erker participate in research or clinical trials?

Yes. Dr. Craig Erker has published 43 articles and abstracts on conditions like Glioma. You can view a list of Dr. Craig Erker's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Erker's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile